98%
921
2 minutes
20
Background And Objectives: Standard therapies (adrenocorticotropic hormone [ACTH], oral steroids, or vigabatrin) fail to control infantile spasms in almost half of children. Early identification of nonresponders could enable rapid initiation of sequential therapy. We aimed to determine the time to clinical remission after appropriate infantile spasms treatment initiation and identify predictors of the time to infantile spasms treatment response.
Methods: The National Infantile Spasms Consortium prospectively followed children aged 2-24 months with new-onset infantile spasms at 23 US centers (2012-2018). We included children treated with standard therapy (ACTH, oral steroids, or vigabatrin). Sustained treatment response was defined as having the last clinically recognized infantile spasms on or before treatment day 14, absence of hypsarrhythmia on EEG 2-4 weeks after treatment, and persistence of remission to day 30. We analyzed the time to treatment response and assessed clinical characteristics to predict sustained treatment response.
Results: Among 395 infants, clinical infantile spasms remission occurred in 43% (n = 171) within the first 2 weeks of treatment, of which 81% (138/171) responded within the first week of treatment. There was no difference in the median time to response across standard therapies (ACTH: median 4 days, interquartile range [IQR] 3-7; oral steroids: median 3 days, IQR 2-5; vigabatrin: median 3 days, IQR 1-6). Individuals without hypsarrhythmia on the pretreatment EEG (i.e., abnormal but not hypsarrhythmia) were more likely to have early treatment response than infants with hypsarrhythmia at infantile spasms onset (hazard ratio 2.23, 95% CI 1.39-3.57). No other clinical factors predicted early responders to therapy.
Discussion: Remission after first infantile spasms treatment can be identified by treatment day 7 in most children. Given the importance of early and effective treatment, these data suggest that children who do not respond to standard infantile spasms therapy within 1 week should be reassessed immediately for additional standard treatment. This approach could optimize outcomes by facilitating early sequential therapy for children with infantile spasms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728034 | PMC |
http://dx.doi.org/10.1212/WNL.0000000000201232 | DOI Listing |
Mol Genet Genomic Med
September 2025
Research Centre for Medical Genetics, Moscow, Russia.
Background: Developmental and epileptic encephalopathies (DEEs) comprise a diverse range of disorders that can arise from both genetic and non-genetic causes. Genetic DEEs are linked to pathogenic variants in various genes with different molecular functions. The wide clinical and genetic variability found in DEEs poses a considerable challenge for accurate diagnosis even with the use of comprehensive diagnostic approaches such as whole genome sequencing (WGS).
View Article and Find Full Text PDFImmune Netw
August 2025
Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul 03722, Korea.
Developmental and epileptic encephalopathies (DEEs), including Infantile Epileptic Spasms Syndrome (IESS) and Lennox-Gastaut Syndrome (LGS), are severe pediatric conditions characterized by profound developmental delays and treatment-resistant epilepsy. Although steroid therapies provide some clinical benefits, the underlying immunological mechanisms remain poorly understood. In this study, we performed comprehensive immune profiling using multi-parametric flow cytometry on PBMCs from IESS (n=25) and LGS (n=9) patients, comparing them with age-matched healthy controls (n=54).
View Article and Find Full Text PDFBehav Brain Res
September 2025
Department of Pharmacology, Research Block B, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India. Electronic address:
Infantile Epileptic Spasms Syndrome (IESS), also referred to as West syndrome, is a severe epileptic disorder that emerges during early childhood. It is marked by characteristic epileptic spasms, developmental stagnation or regression, and a distinctive electroencephalogram (EEG) pattern known as hypsarrhythmia. To better understand the underlying mechanisms of IESS, various genetic and chemically induced animal models have been developed.
View Article and Find Full Text PDFEpilepsy Behav
September 2025
Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Objective: Electronic health records offer the opportunity for quality-improvement (QI) initiatives addressing health disparities in epilepsy care. The Pediatric Epilepsy Outcome-Informatics Project (PEOIP) at Alberta Children's Hospital implemented point-of-care data entry into a standardized pediatric epilepsy electronic note as part of routine clinical care to support QI initiatives. Our study validated collected data by assessing the prevalence of patient characteristics, ethno-racial background, and 4 of the most common severe epilepsy syndromes: infantile epileptic spasms, Dravet, Lennox-Gastaut, and developmental epileptic encephalopathy with spike-wave action in sleep.
View Article and Find Full Text PDFPediatr Neurol
August 2025
Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Background: The Burden of AmplitudeS and Epileptiform Discharges (BASED) and "Hypsarrhythmia Scoring System" (HSS) serve to evaluate the interictal EEG in infantile epileptic spasms (ES) syndrome (IESS). We aimed to assess these scoring systems' reliability and diagnostic utility in infants with IESS and other developmental and epileptic encephalopathies (DEEs) without ES.
Methods: Three epileptologists from a single medical center scored the deidentified EEG tracings of 110 infants, 58 with IESS, and 52 with other DEEs (of similar age and sex distributions), according to the BASED and HSS scoring systems.